130 billion won of amlodipine sales by domestic drug companies.

Published: 2004-09-07 06:58:00

Updated: 2004-09-07 06:58:00

Amid a feverish promotional war on amlodipine markets among the domestic drug companies to preoccupy its shares, the 2005 sales targets estimated 130 billion won for 4 different amlodipine competitors, SK's Skad, Hanmi's Amodipine, CKD's Anydipine and Choongwe's Novalopine that would be launched ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK